Periorbital necrotizing fasciitis.
Elwood
Eric T
ET
Peoria, Ill.; and Columbia, Mo. From the Division of Plastic and Reconstructive Surgery, University of Illinois College of Medicine at Peoria, and Department of Ophthalmology, The Mason Eye Institute, University of Missouri School of Medicine.
Sommerville
Drew N
DN
Murray
John D
JD
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D002939:Ciprofloxacin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003607:Dacryocystitis / Q000188:drug therapy / Q000209:etiology*; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005141:Eyelid Diseases / Q000209:etiology*; D019115:Fasciitis, Necrotizing / Q000209:etiology*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008408:Mastectomy; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D004317:Doxorubicin; D003520:Cyclophosphamide